Bioniche Granted First Major Composition Patent for Oligonucleotide Technology
Dr. Nigel C. Phillips, Chief Scientific Officer for Bioniche Life Sciences Inc. stated, "This patent consolidates our oligonucleotide patent portfolio. These oligonucleotides constitute a new composition family that enhances our ability to develop effective treatments for oncology indications. Bioniche now has technology platforms based on mycobacterial cell walls, unmodified oligonucleotides and modified oligonucleotides that have immune stimulant and anticancer activity. Bioniche is in a position to develop effective treatments for cancer using these unique and complementary technology platforms."
In 2000, Bioniche announced the discovery of a new class of molecules with potential anticancer activity, referred to by the Company under the trademark, "Oligomodulator(TM)". This new class of molecules with potential clinical anticancer activity and immune modulating properties is composed of short non-antisense DNA oligonucleotides that appear to possess a range of novel pharmacological activities.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.